Combination Antifungal Therapy for Invasive Aspergillosis | Zendy

Kieren A. Marr | Zendy; Michael Boeckh | Zendy; R. A. Carter | Zendy; Hye Won Kim | Zendy; Lawrence Corey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination Antifungal Therapy for Invasive Aspergillosis

Author(s) -

Kieren A. Marr,

Michael Boeckh,

R. A. Carter,

Hye Won Kim,

Lawrence Corey

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/423380

Subject(s) - echinocandins , aspergillosis , medicine , amphotericin b , combination therapy , antifungal , mycosis , aspergillus , microbiology and biotechnology , immunology , caspofungin , biology , dermatology

Aspergillosis therapy with amphotericin, azoles, or echinocandins is associated with substantial mortality, ranging from 30% to 80%, depending on the stage of infection and the host's underlying disease. The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research